Retlirafusp plus chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (retlirafusp alfa) combined with standard chemotherapy given before surgery to treat esophageal squamous cell carcinoma—a type of cancer in the food tube. The goal is to shrink the tumor before removal and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma (a specific type of food tube cancer) confirmed by biopsy
- Your cancer is in the chest area and at a specific stage (T1b-4aN+ or T2-4aN0 by AJCC staging) that your doctor thinks can be completely removed by surgery
- You are 18–75 years old and in good enough health to tolerate chemotherapy and surgery (ECOG score 0–1)
- You have not received any prior chemotherapy, radiation, or surgery for esophageal cancer
- Your blood counts and organ function (liver, kidney, heart) are adequate, based on recent lab tests
- You are willing to complete neoadjuvant (pre-surgery) therapy and then have surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
This trial tests a combination of an immunotherapy drug (serplulimab) and two chemotherapy drugs (nab-paclitaxel and cisplatin) given before surgery for esophageal cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improve outcomes for patients with stage IB to III esophageal squamous cell carcinoma.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.